Onset of multiple sclerosis associated with anti-TNF therapy.
about
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetesTumour Necrosis Factor Modulation for Treatment of Alzheimerʼs DiseaseCurrent Concepts in Multiple Sclerosis: Autoimmunity Versus OligodendrogliopathyAnti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetyThe intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the gamesCreation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonistA comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabAdalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the LiteratureBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetilFingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.Multiple sclerosis susceptibility alleles in African Americans.Anti-TNF-alpha therapies in systemic lupus erythematosusA practical approach to monitoring patients on biological agents for the treatment of psoriasisRegulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12).Monoclonal antibodies in multiple sclerosis treatment: current and future steps.Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathwayAdvances in understanding the genetic basis of rheumatoid arthritis and osteoarthritis: implications for therapy.Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.Poly(I:C) promotes TNFα/TNFR1-dependent oligodendrocyte death in mixed glial cultures.Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis.The German etanercept registry for treatment of juvenile idiopathic arthritis.Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosisAnti-TNF-alpha therapy for sight threatening uveitis.Cytokine disturbances in systemic lupus erythematosus.Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences.The neuroprotective role of inflammation in nervous system injuries.Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis.Analysis of a Functional IL-6 Gene Polymorphism in HLAB27 Associated and Intermediate Uveitis Gives New Insight in Disease Pathogenesis and Commonality with Other Autoimmune DiseasesIL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritisTumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.Drug insight: using monoclonal antibodies to treat multiple sclerosis.A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response.Soluble Tumor Necrosis Factor Receptor 1 Released by Skin-Derived Mesenchymal Stem Cells Is Critical for Inhibiting Th17 Cell Differentiation.Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.
P2860
Q21134119-C4866E3E-163C-4622-AA5F-F2CF3B102DBBQ22241425-49520ADB-0280-48D0-BF1F-ED78A39CF35CQ22252578-7391DB48-E3D2-48E6-B02A-13296B830B78Q24673716-5B09C62B-D228-4C86-9BC4-DC6F938042A5Q24683018-C776DD96-0366-42AF-95AF-E072C6623936Q27649040-895E9772-7F75-4B6E-B55E-029789AA0151Q28282330-5B4BD610-605D-4098-8052-B9A63A29B20FQ30047634-85BB1FBF-4055-49D9-AAD4-D5EDB7D48CBBQ30412650-254415CA-54DB-4FC5-9EE3-BE00E5642A70Q30577403-9BD1E359-E7AB-416C-903E-3B3E4EF9438AQ30647378-CDAC4853-82E6-4931-92CE-2EE3F7A29A53Q33403151-D79D2EA5-49BE-4832-9DB6-7378195A5AB3Q33727962-7AEF8CBF-340B-42DC-B53E-E83E37A60207Q33892035-916BBAEB-C70F-4E9B-A94E-8E4034B6553EQ33960066-85AEF3DF-D001-4BA3-A78B-052450D917C4Q34156420-CD6949D5-24F0-4237-AEFA-09E2C322179BQ34235574-C6AE7DD5-E168-4E27-BA05-C8E0181CBC50Q34409404-AB758297-6B15-47AF-911D-62D90294D5B5Q34413324-758398D6-ADA2-4706-A21F-55CCA384C516Q34501045-313FD04D-450A-4FB2-A3D8-638DC537676BQ34620355-6485D053-57A7-4789-9EE4-4A96F746BE81Q34939962-1C8F6BA9-760C-42FD-9F30-84F76C1143C9Q34991438-5AA8D724-A764-455E-BBE0-C04B8EB79282Q35108700-76AD2DD6-7DB8-43AF-90D0-090DD787795CQ35184144-36B6CCA2-0E00-4622-8ACA-0020431E94DCQ35216972-2F6F3180-2A6B-4470-90E1-F4951DA1ED1CQ35553680-6F8A73A6-577E-4DB0-9045-7F0412FF2F93Q35577914-F046DE6A-D25B-48DD-8B8F-74D5A5F4890FQ35593155-BE847A22-7ED0-4101-BAF4-A1EAE0E8FA8DQ35617573-D31BB8A7-51DD-4516-A5A6-4B671B91FF7DQ35843827-049F6D2D-82BB-4200-9E79-0775A12683B7Q35981187-225029BE-D7A1-490C-B980-CA6815B78A84Q35989499-E12BFB01-591B-4D46-AE92-12050FE9AB67Q36310417-EFBC8B91-4FA8-4CB4-ABCB-D29E9636B8C1Q36512506-886EB7A2-7337-4A18-903E-307F941D1975Q36574105-8CD81B48-EE9B-4E40-B299-BF6BD46ED568Q36577212-5F3C4004-EC57-4F38-808C-D53FB37088D1Q36654727-58049A99-D145-48C9-8D06-4FD1B88AA3D4Q36728560-218F13C0-E63C-4E8A-8D51-6DB8B39E6CEBQ36734084-7F1014F5-8317-4BD7-B451-68368D0FCFAE
P2860
Onset of multiple sclerosis associated with anti-TNF therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Onset of multiple sclerosis associated with anti-TNF therapy.
@en
Onset of multiple sclerosis associated with anti-TNF therapy.
@nl
type
label
Onset of multiple sclerosis associated with anti-TNF therapy.
@en
Onset of multiple sclerosis associated with anti-TNF therapy.
@nl
prefLabel
Onset of multiple sclerosis associated with anti-TNF therapy.
@en
Onset of multiple sclerosis associated with anti-TNF therapy.
@nl
P921
P356
P1433
P1476
Onset of multiple sclerosis associated with anti-TNF therapy.
@en
P2093
Sicotte NL
Voskuhl RR
P304
P356
10.1212/WNL.57.10.1885
P407
P577
2001-11-01T00:00:00Z